A

patient taking an experimental cancer drug from Kite Pharma died after experiencing severe brain swelling, the company said Monday.

The news sparked alarm on the heels of a series of patient deaths at competitor Juno Therapeutics, which is developing the same type of cutting-edge cancer immunotherapy, called CAR-T. The report may raise caution about the immunotherapy drugs that have sparked sky-high hopes even as their downsides have become increasingly apparent.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.